Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 10/20 | 0.70 |
| ▸ | NPC1 | O15118 | 6/20 | 0.70 |
| ▸ | ABL1 | P00519 | 2/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.68 |
| ▸ | LMNA | P02545 | 3/20 | 0.68 |
| ▸ | MAPT | P10636 | 3/20 | 0.68 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.68 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 5/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.65 |
| ▸ | GSK3B | P49841 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.60 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.60 |
| ▸ | RELA | Q04206 | 2/20 | 0.60 |
| ▸ | AR | P10275 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2559540 | 0.93 | RAB9A (0.65) | RAB9ANPC1ABL1SMN1; SMN2KDM4E | |
| SCHEMBL14758306 | 0.85 | KDM4E (0.70) | RAB9ANPC1ABL1SMN1; SMN2KDM4E | |
| SCHEMBL30581066 | 0.84 | RAB9A (0.78) | RAB9ANPC1SMN1; SMN2KDM4EMAPT | |
| SCHEMBL5577096 | 0.83 | RAB9A (0.62) | RAB9ANPC1ABL1SMN1; SMN2KDM4E | |
| SCHEMBL7241453 | 0.83 | RAB9A (0.65) | RAB9ANPC1ABL1SMN1; SMN2KDM4E | |
| SCHEMBL24026399 | 0.82 | RAB9A (0.74) | RAB9ANPC1SMN1; SMN2KDM4ELMNA | |
| SCHEMBL7239435 | 0.81 | RAB9A (0.61) | RAB9ANPC1SMN1; SMN2KDM4ELMNA | |
| SCHEMBL27911241 | 0.80 | KDM4E (0.70) | RAB9ANPC1ABL1SMN1; SMN2KDM4E | |
| SCHEMBL15689170 | 0.80 | ABL1 (0.74) | RAB9ANPC1ABL1SMN1; SMN2KDM4E | |
| SCHEMBL17107238 | 0.80 | RAB9A (0.70) | RAB9ANPC1ABL1SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140329863-A1 | NOVEL ANTIPRION COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140329863-A1 | NOVEL ANTIPRION COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-11-06 | — | — | US | disclosed |
| WO-2013033037-A2 | NOVEL ANTIPRION COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-03-07 | — | — | WO | disclosed |
| WO-2003006443-A2 | 2- 4-(NAPHTALIN-2-YL)-THIAZOL-2-YLAMINOCARBONYL BENZOIC ACID AND 2- 4-(NAPHTALIN-2-YL)-PYRIMIDIN-2-YLAMINOCARBONYL BENZOIC ACID AND ADDITIONAL COMPOUNDS SERVING AS TELOMERASE INHIBITORS FOR USE IN TUMOR THERAPY | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329863-A1 | NOVEL ANTIPRION COMPOUNDS | PRNP, PSEN1, PSEN2 | RAB9A 1779/4885NPC1 57/4885ABL1 4772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.